Estrella Immunopharma’s (ESLA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Estrella Immunopharma (NASDAQ:ESLA) in a report published on Monday,Benzinga reports. They currently have a $16.00 price objective on the stock.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Estrella Immunopharma in a research report on Friday, October 31st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Estrella Immunopharma currently has a consensus rating of “Hold” and an average target price of $16.00.

Estrella Immunopharma Stock Performance

ESLA opened at $2.56 on Monday. The business has a 50 day moving average price of $1.52 and a 200 day moving average price of $1.15. Estrella Immunopharma has a twelve month low of $0.70 and a twelve month high of $3.15. The firm has a market cap of $94.90 million, a P/E ratio of -8.53 and a beta of 0.52.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.